Chinese University of Hong Kong

Hong Kong and Singapore lead green fintech development among the Five Economies in APEC

Retrieved on: 
Friday, October 28, 2022

HONG KONG and SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Today, GoImpact, an ESG and Sustainability education firm, together with The Chinese University of Hong Kong's Business School ("CUHK Business School") released the findings from their working paper, Exploring the Green Fintech Ecosystem in Asia: Insights from Five Economies in APEC. This study finds that government support plays a vital and essential role in facilitating green fintech development, while talent shortage is a common concern in the five economies in the region.

Key Points: 
  • Derived from three elements environment, finance, and technology the industry report defines green fintech as financial activities that utilize green technologies that bring better environmental outcomes.
  • Industry experts from five APEC economies, namely Hong Kong SAR, China ("Hong Kong"), Indonesia, the Republic of Korea ("Korea"), Singapore and Thailand, have urged policymakers to establish a conducive environment for green fintech to flourish.
  • Key findings from the study include the following:
    Green fintech startups in Asia have already provided many different types of green fintech, such as green digital payment, green digital investment solutions, digital green analytics, green crowdfunding, green risk analysis, green digital lending, green digital asset solutions, and green regtech.
  • It will raise awareness, push the demand for green finance, and cultivate the talent needed for green FinTech Development in Asia.

EQS-News: A New BioTech Research Race Is Focused On Improving Life For MS Patients

Retrieved on: 
Friday, October 28, 2022

As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.

Key Points: 
  • As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.
  • The rising MS numbers are believed to be the primary catalyst in market expansion.
  • Some are finding new research showing that an mRNA vaccine might also work in multiple sclerosis (MS).
  • Another recent article in Science showed published research that scientists have discovered about the risk of an individual contracting MS.

The 2022 World Dongguan Entrepreneurs Convention and Semiconductor Industry Development Forum Was Held in Dongguan City

Retrieved on: 
Wednesday, August 31, 2022

Dongguan, China--(Newsfile Corp. - August 31, 2022) - The 2022 World Dongguan Entrepreneurs Convention and Semiconductor Industry Development Forum was held in Dongguan City.

Key Points: 
  • Dongguan, China--(Newsfile Corp. - August 31, 2022) - The 2022 World Dongguan Entrepreneurs Convention and Semiconductor Industry Development Forum was held in Dongguan City.
  • Under the guidance of the Economic Daily, the forum was hosted by the Dongguan Municipal Party Committee and the Dongguan Municipal People's Government.
  • The theme of the forum was "deeply integrating into the Guangdong-Hong Kong-Macao Greater Bay Area and building a new pattern of development."
  • Hopefully Dongguan will continue to put more effort into special investments in science and technology, supporting the industry's concentrated development.

Alibaba Group Appoints Two Independent Directors with Enhanced Corporate Governance

Retrieved on: 
Thursday, August 4, 2022

The new appointments demonstrate the Companys commitment to corporate governance excellence and diversity at the board level.

Key Points: 
  • The new appointments demonstrate the Companys commitment to corporate governance excellence and diversity at the board level.
  • Following these appointments, the Companys board currently consists of twelve directors, including seven independent directors.
  • The new independent board member appointments are part of Alibabas ongoing enhancement of our corporate governance.
  • I am delighted to join Alibaba, with its mission to make it easier to do business with anyone, anywhere.

Introducing the Man Behind KingsArts: Dr. Raymond Wong Launches New Contemporary Art Platform

Retrieved on: 
Tuesday, July 19, 2022

HONG KONG, July 19, 2022 (GLOBE NEWSWIRE) -- In an effort to empower both contemporary artists and art collectors on a global scale, Dr. Raymond Wong has launched KingArts, a contemporary art trading platform.

Key Points: 
  • HONG KONG, July 19, 2022 (GLOBE NEWSWIRE) -- In an effort to empower both contemporary artists and art collectors on a global scale, Dr. Raymond Wong has launched KingArts, a contemporary art trading platform.
  • A man of vision, Dr. Wong aims to bring Chinese history and culture to the forefront of the contemporary art world by showcasing unique pieces of work that have interesting stories and history behind them.
  • To learn more about the KingArts platform and for more information on Dr. Raymond Wong's illustrious career, please visit http://kingsarts.com/#/ .
  • We build a transparent and innovative business model for all parties, including artists, art investors, and art collectors.

ZAP Surgical Announces Chairman of Foxconn Technology Joins Board of Directors

Retrieved on: 
Thursday, June 30, 2022

ZAP Surgical Systems, Inc., developer and manufacturer of the ZAP-X surgical robot for non-invasive ablation of brain tumors, today announced that the Chairman of Foxconn Technology Co Ltd, Lu Jun-Fu (Stanley Lu), has joined the ZAP Surgical Board of Directors.

Key Points: 
  • ZAP Surgical Systems, Inc., developer and manufacturer of the ZAP-X surgical robot for non-invasive ablation of brain tumors, today announced that the Chairman of Foxconn Technology Co Ltd, Lu Jun-Fu (Stanley Lu), has joined the ZAP Surgical Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20220630005845/en/
    Mr. Terry Guo, Founder, Chairman and Chief Executive Officer of Foxconn, visiting ZAP Surgical Headquarters in San Carlos, CA.
  • Stanley Lu is the Chairman of Foxconn Technology Co Ltd, elected in October 2021.
  • Prior, Stanley was the Chief Financial Officer and spokesperson of Foxsemicon Integrated Technology Inc.
    Terry Guo, founder and former Chairman and Chief Executive Officer of Foxconn, co-founded ZAP Surgical in 2014, and contributed entrepreneurial expertise and his anchor investment established ZAP Surgical as an independent company.

China Daily series Youth Power:Gen Zers discuss "One country, two systems, three cheers"

Retrieved on: 
Thursday, June 30, 2022

TheGen Zers who took part discussed childhood memories and identity and cultural differences relating to Hong Kong and the mainland.

Key Points: 
  • TheGen Zers who took part discussed childhood memories and identity and cultural differences relating to Hong Kong and the mainland.
  • For example, Cantonese songs, TV programs, Hong Kong stars and celebrities and other elements of Hong Kong pop culture are a common memory and love of Gen Zers.
  • Gen Zers in Hong Kong and Macao also enjoy variety shows from the mainland.
  • Those in the program said they hoped people from both Hong Kong and the mainland would cherish their shared history and culture.

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Retrieved on: 
Wednesday, June 22, 2022

OXFORD, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from the HBV002 study (NCT04778904), which is being presented as a poster at the 2022 EASL International Liver CongressTM by Professor Ellie Barnes, Professor of Hepatology and Experimental Medicine at the University of Oxford.

Key Points: 
  • Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose.
  • In the VTP-300 monotherapy group, meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL.
  • These three patients had 0.7, 0.7 and 1.4 log10 declines two months after the last dose of VTP-300.
  • These dramatic declines have persisted in all three patients at their latest follow-up at five or eight months after the last dose of VTP-300.

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Retrieved on: 
Tuesday, June 7, 2022

A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

Key Points: 
  • A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).
  • Another clinical study called SENSITIZE also provided clinical scientific data of dorzagliatin in improving insulin secretion and glucose sensitivity.
  • The study results, using glucose clamp technique, showed that dorzagliatin can significantly improve second phase insulin secretion and glucose sensitivity in GCK-MODY patients and can significantly improve basal insulin secretion rates in patients with recent onset T2D.
  • Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China.

CUHK Professor Elaine Chow Receives "2022 Women's Interprofessional Network of the American Diabetes Association Abstract Award" for Outstanding Research and Care in Diabetes

Retrieved on: 
Sunday, June 5, 2022

The WIN ADA abstract award category of Clinical Diabetes, Epidemiology, and Diabetes Complications is an important part of WIN ADA awards, voted by WIN ADA Advisory Group, consisting of expert clinicians, scientists, educators, public health practitioners, and other diabetes professionals.

Key Points: 
  • The WIN ADA abstract award category of Clinical Diabetes, Epidemiology, and Diabetes Complications is an important part of WIN ADA awards, voted by WIN ADA Advisory Group, consisting of expert clinicians, scientists, educators, public health practitioners, and other diabetes professionals.
  • It honours women who have made significant contributions to the diabetes research, clinical care, public health, education, and related areas worldwide.
  • The award was presented to Professor Elaine on June 3, 2022.
  • Professor Elaine will present a clinical study called SENSITIZE, which explored the effects of dorzagliatin, the global first-in-class drug, glucokinase activator (GKA) at the ADA Annual Scientific Sessions.